Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors.
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
28
07
2022
received:
10
03
2022
accepted:
03
08
2022
pubmed:
10
8
2022
medline:
22
11
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
Prompt differential diagnosis of liver tumors is clinically important and sometimes difficult. A new diagnostic device that combines probe electrospray ionization-mass spectrometry (PESI-MS) and machine learning may help provide the differential diagnosis of liver tumors. We evaluated the diagnostic accuracy of this new PESI-MS device using tissues obtained and stored from previous surgically resected specimens. The following cancer tissues (with collection dates): hepatocellular carcinoma (HCC, 2016-2019), intrahepatic cholangiocellular carcinoma (ICC, 2014-2019), and colorectal liver metastasis (CRLM, 2014-2019) from patients who underwent hepatic resection were considered for use in this study. Non-cancerous liver tissues (NL) taken from CRLM cases were also incorporated into the analysis. Each mass spectrum provided by PESI-MS was tested using support vector machine, a type of machine learning, to evaluate the discriminatory ability of the device. In this study, we used samples from 91 of 139 patients with HCC, all 24 ICC samples, and 103 of 202 CRLM samples; 80 NL from CRLM cases were also used. Each mass spectrum was obtained by PESI-MS in a few minutes and was evaluated by machine learning. The sensitivity, specificity, and diagnostic accuracy of the PESI-MS device for discriminating HCC, ICC, and CRLM from among a mix of all three tumors and from NL were 98.9%, 98.1%, and 98.3%; 87.5%, 93.1%, and 92.6%; and 99.0%, 97.9%, and 98.3%, respectively. This study demonstrated that PESI-MS and machine learning could discriminate liver tumors accurately and rapidly.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Prompt differential diagnosis of liver tumors is clinically important and sometimes difficult. A new diagnostic device that combines probe electrospray ionization-mass spectrometry (PESI-MS) and machine learning may help provide the differential diagnosis of liver tumors.
METHODS
METHODS
We evaluated the diagnostic accuracy of this new PESI-MS device using tissues obtained and stored from previous surgically resected specimens. The following cancer tissues (with collection dates): hepatocellular carcinoma (HCC, 2016-2019), intrahepatic cholangiocellular carcinoma (ICC, 2014-2019), and colorectal liver metastasis (CRLM, 2014-2019) from patients who underwent hepatic resection were considered for use in this study. Non-cancerous liver tissues (NL) taken from CRLM cases were also incorporated into the analysis. Each mass spectrum provided by PESI-MS was tested using support vector machine, a type of machine learning, to evaluate the discriminatory ability of the device.
RESULTS
RESULTS
In this study, we used samples from 91 of 139 patients with HCC, all 24 ICC samples, and 103 of 202 CRLM samples; 80 NL from CRLM cases were also used. Each mass spectrum was obtained by PESI-MS in a few minutes and was evaluated by machine learning. The sensitivity, specificity, and diagnostic accuracy of the PESI-MS device for discriminating HCC, ICC, and CRLM from among a mix of all three tumors and from NL were 98.9%, 98.1%, and 98.3%; 87.5%, 93.1%, and 92.6%; and 99.0%, 97.9%, and 98.3%, respectively.
CONCLUSION
CONCLUSIONS
This study demonstrated that PESI-MS and machine learning could discriminate liver tumors accurately and rapidly.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2182-2188Informations de copyright
© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Banales JM, Cardinale V, Carpino G et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 2016; 13: 261-280.
Itai Y, Saida Y. Pitfalls in liver imaging. Eur. Radiol. 2002; 12: 1162-1174.
Ariff B, Lloyd CR, Khan S et al. Imaging of liver cancer. World J. Gastroenterol. 2009; 15: 1289-1300.
Arita J, Ono Y, Takahashi M et al. Routine Preoperative Liver-specific Magnetic Resonance Imaging Does Not Exclude the Necessity of Contrast-enhanced Intraoperative Ultrasound in Hepatic Resection for Colorectal Liver Metastasis. Ann. Surg. 2015; 262: 1086-1091.
Takahashi M, Hasegawa K, Arita J et al. Contrast-enhanced intraoperative ultrasonography using perfluorobutane microbubbles for the enumeration of colorectal liver metastases. Br. J. Surg. 2012; 99: 1271-1277.
Howanitz PJ, Hoffman GG, Zarbo RJ. The accuracy of frozen-section diagnoses in 34 hospitals. Arch. Pathol. Lab. Med. 1990; 114: 355-359.
Haj-Mirzaian A, Kadivar A, Kamel IR, Zaheer A. Updates on Imaging of Liver Tumors. Curr. Oncol. Rep. 2020; 22: 46.
Li B, Li B, Guo T et al. Application Value of Mass Spectrometry in the Differentiation of Benign and Malignant Liver Tumors. Med. Sci. Monit. 2017; 23: 1636-1644.
Ressom HW, Varghese RS, Goldman L et al. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J. Proteome Res. 2008; 7: 603-610.
Yoshimura K, Mandal MK, Hara M et al. Real-time diagnosis of chemically induced hepatocellular carcinoma using a novel mass spectrometry-based technique. Anal. Biochem. 2013; 441: 32-37.
Ishii H, Saitoh M, Sakamoto K et al. Lipidome-based rapid diagnosis with machine learning for detection of TGF-β signalling activated area in head and neck cancer. Br. J. Cancer 2020; 122: 995-1004.
Ashizawa K, Yoshimura K, Johno H et al. Construction of mass spectra database and diagnosis algorithm for head and neck squamous cell carcinoma. Oral Oncol. 2017; 75: 111-119.
Saito R, Yoshimura K, Shoda K et al. Diagnostic significance of plasma lipid markers and machine learning-based algorithm for gastric cancer. Oncol. Lett. 2021; 21: 405.
Kiritani S, Yoshimura K, Arita J et al. A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis. BMC Cancer 2021; 21: 262.
Takeda S, Yoshimura K, Tanihata H. Sample Preparation for Probe Electrospray Ionization Mass Spectrometry. J. Vis. Exp. 2020.
Yoshimura K, Yamada Y, Ninomiya S et al. Real-time analysis of living animals and rapid screening of human fluid samples using remote sampling electrospray ionization mass spectrometry. J. Pharm. Biomed. Anal. 2019; 172: 372-378.
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.
Pittman ME, Yantiss RK. Frozen Sections of the Liver. Surg Pathol Clin. 2018; 11: 453-466.
Dong Y, Patel H, Patel C. Intrabiliary Hepatic Metastasis of Colorectal Carcinoma Mimicking Primary Cholangiocarcinoma: A Case Report and Review of the Literature. Case Rep Pathol. 2016; 2016: 4704781.
Chiu CT, Chiang JM, Yeh TS et al. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges? Dig. Liver Dis. 2008; 40: 749-754.
Park JH, Kim JH. Pathologic differential diagnosis of metastatic carcinoma in the liver. Clin. Mol. Hepatol. 2019; 25: 12-20.
Giordano S, Takeda S, Donadon M et al. Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. Liver Int. 2020; 40: 3117-3124.
Ferrarini A, Di Poto C, He S et al. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma. J. Proteome Res. 2019; 18: 3067-3076.
Nagai K, Uranbileg B, Chen Z et al. Identification of novel biomarkers of hepatocellular carcinoma by high-definition mass spectrometry: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry and desorption electrospray ionization mass spectrometry imaging. Rapid Commun. Mass Spectrom. 2020; 34: e8551.
Johno H, Yoshimura K, Mori Y et al. Detection of potential new biomarkers of atherosclerosis by probe electrospray ionization mass spectrometry. Metabolomics. 2018; 14: 38.
Usmanov DT, Ninomiya S, Chen LC et al. Desorption in Mass Spectrometry. Mass Spectrom (Tokyo). 2017; 6: S0059.
Iwano T, Yoshimura K, Inoue S et al. Breast cancer diagnosis based on lipid profiling by probe electrospray ionization mass spectrometry. Br. J. Surg. 2020; 107: 632-635.
Rakha E, Ramaiah S, McGregor A. Accuracy of frozen section in the diagnosis of liver mass lesions. J. Clin. Pathol. 2006; 59: 352-354.
Sakamoto T, Furukawa T, Lami K et al. A narrative review of digital pathology and artificial intelligence: focusing on lung cancer. Transl Lung Cancer Res. 2020; 9: 2255-2276.
Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750.
Akabane S, Ohira M, Kobayashi T et al. Intrahepatic cholangiocarcinoma coinciding with a liver metastasis from a rectal carcinoma: a case report. Surg Case Rep. 2016; 2: 94.
Fukuhara S, Iwasaki E, Iwano T et al. New strategy for evaluating pancreatic tissue specimens from endoscopic ultrasound-guided fine needle aspiration and surgery. JGH Open. 2021; 5: 953-958.
Hiraoka K, Ariyada O, Usmanov DT et al. Probe Electrospray Ionization (PESI) and Its Modified Versions: Dipping PESI (dPESI), Sheath-Flow PESI (sfPESI) and Adjustable sfPESI (ad-sfPESI). Mass Spectrom (Tokyo). 2020; 9: A0092.
Llovet JM, Vilana R, Brú C et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-1129.
Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 2015; 22: 114-123.
Kim KH, Lee SG, Park EH et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann. Surg. Oncol. 2009; 16: 623-629.
Ishii T, Ito T, Sumiyoshi S et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J. Surg. Oncol. 2020; 18: 319.